Diabetes / Metabolic
Diabetes and metabolic medicine updates, trial evidence, drug mechanisms and CPD resources across glucose lowering, weight management and cardiometabolic risk.
Latest Guidelines
2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease
This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic. Use it to review current recommendation wording, eligibility criteria, and…
2023 ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes
Joint consensus update prioritising SGLT2 inhibitors and GLP-1 receptor agonists based on cardiovascular and renal comorbidities. Introduces individualised glucose targets and deprescribing guidance.
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services or trained general practice…
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m² or BMI ≥27 kg/m²…
Gestational Diabetes: Diagnosis and Treatment (NICE NG3)
Perform a 2-hour 75 g OGTT between 24–28 weeks in women with GDM risk factors; diagnose GDM if fasting glucose ≥5.6 mmol/L or 2-hour glucose ≥7.8…
Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE NG49)
Use FIB-4 or NAFLD Fibrosis Score in primary care to stratify fibrosis risk in adults with metabolic risk factors (type 2 diabetes, obesity, metabolic syndrome); refer…
Trial Radar
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
A new drug combined with tirzepatide tested against tirzepatide alone for weight loss in overweight or obese adults…
PHASE2SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
What is being tested: SAB-142, a human anti-thymocyte immunoglobulin, is being evaluated to determine whether it can arrest…
TrialScottish Advanced Fetal Research Study
Study examining how maternal smoking, alcohol, drugs and environmental exposures affect fetal development and long-term health outcomes.
NAAssessing the Dose-response of Muscle Protein Synthesis to “Super-whey” in Older Adults
One-sentence summary: This study tests three doses of leucine-enriched whey protein to find which best stimulates muscle building…
Clinical News
Daily pill to help keep weight off after stopping obesity jabs
Orforglipron is a daily oral tablet offering an alternative to GLP-1 receptor agonist injections for weight maintenance after…
27 Apr 2026UK healthy life expectancy falls by two years in past decade
UK healthy life expectancy has declined by two years over the past decade, representing a significant reversal in…
17 Apr 2026Mental health support to be offered to people with diabetes in UK first
People with diabetes have double the risk of depression compared to the general population, highlighting the need for…
17 Apr 2026Poetry, rhyme and rhythm saved my life
People with diabetes have double the risk of depression compared to the general population, highlighting need for routine…
Relevant Mechanisms
GLP-1 Receptor Agonism
GLP-1 Receptor Agonism is a clinically relevant Drug Science explainer. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal…
MechanismHMG-CoA Reductase — Statins
HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step…
MechanismPCSK9 Inhibition
PCSK9 Inhibition is a clinically relevant Drug Science explainer. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted…
MechanismSGLT-2 Inhibition
SGLT-2 Inhibition is a clinically relevant Drug Science explainer. Sodium-glucose cotransporter-2 (SGLT-2) is a high-capacity, low-affinity transporter expressed almost exclusively…
CPD, Podcasts & Webinars
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
webinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
podcastGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide…
podcastSGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, causing glycosuria with effects that extend beyond HbA1c…
cpd moduleNICE NG28: Type 2 Diabetes in Adults — 2024 Update
Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists…
cpd moduleCardiovascular Risk Reduction — Latest Evidence 2024
Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification. Apply statin, ezetimibe, PCSK9 inhibitor…
Follow Diabetes / Metabolic safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Diabetes / Metabolic
Choose guideline, trial, Drug Science and education updates for this specialty.